Summary
Twenty-three evaluable patients with advanced gastric adenocarcinoma were treated with trimetrexate at doses of 8–12 mg/m2 intravenously daily for five days, with cycles repeated every 21 days. One complete response was seen for an overall response rate of 4% (95% confidence interval 0–22%). Hematologie toxicities of grade ≥ 3 were seen in 10/23 patients, and overall any grade 3 or greater toxicity was seen in 14/ 23 patients. Trimetrexate has minimal activity against gastric adenocarcinoma in this study, and no further investigation of this agent at this dose and schedule is recommended in this disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Boring CC, Squires TS, Tong T, Montgomery S: Cancer statistics, 1994. Ca 44:7–26, 1994
Panettiere FJ, Haas C, McDonald B, Costanzi JJ, Talley RW, Athens J, Oishi N, Heilbrun LK, Chen TT: Drug combinations in the treatment of gastric adenocarcinoma. A randomized Southwest Oncology Group study. J Clin Oncol 2:420–424, 1984
Bertino JR, Sawicki WL, Moroson BA, Cashmore AR, Elslager EL: 2,4-Diamno-5-methyl-,(3,4,5-trimethoxyanilino) methyl, quinazoline (TMQ), a potent nonclassical folate antagonist inhibitor. I. Effect on dihydrofolate reductase and growth of rodent tumorsin vitro andin vivo. Biochem Pharmacol 28:1983–1987, 1979
Kamen BA, Eibl B, Cashmore A, Bertino J: Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)-methyl]quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cellsin vitro. Biochem Pharmacol 33:1697–1699, 1984
Diddens H, Neithammer D, Jackson RC: Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Cancer Res 50:3284–3288, 1990
Clinical Brochure on Trimetrexate Glucuronate (TMTX), NSC 352122. Bethesda, MD: Division of Cancer Treatment, National Cancer Institute, 1983
Green S, Weiss G: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Inv New Drugs 10:239–253, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hantel, A., Tangen, C.M., Macdonald, J.S. et al. Phase II trial of trimetrexate in untreated advanced gastric carcinoma. Invest New Drugs 12, 155–157 (1994). https://doi.org/10.1007/BF00874448
Issue Date:
DOI: https://doi.org/10.1007/BF00874448